OhmBody, a new "science-forward" division of Spark Biomedical, targets women's monthly period symptoms with $719 earpiece that uses nerve stimulation following Spark's $15M Series A funding round in April.
According to Hazelden Betty Ford, a neurostimulation device made by Spark Biomedical shows promise in helping adults and young adults emerge from addiction.
Final enrollment concludes for Spark Biomedical's pivotal study investigating a non-invasive, drug-free neurostimulation therapy aimed at improving treatment retention for adults with opioid use disorder.
